Athrombopoietin receptor agonist, Eltrombopag has been approvedsince 2010. In 2015, the indication of idiopathic thrombocytopenic purpura (ITP) was extended to include severe aplasticanaemia (SAA), in which other therapies do not strike. No serious side effects have been observed but less severe ones are very common.